MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancerPaul Vilquin(Université Claude Bernard Lyon 1), Pascale A. Cohen(Université Claude Bernard Lyon 1)Breast Cancer ResearchJanuary 29, 201510.1186/s13058-015-0515-1Cited by 79SaveCiteExport RISWatch citationsRelated PapersPhase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i> V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism|Clinical Cancer Research|2021|19